Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Short-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $83.3 million.

  • Myriad Genetics' Accumulated Depreciation & Amortization fell 2898.55% to $83.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.3 million, marking a year-over-year decrease of 2898.55%. This contributed to the annual value of $109.6 million for FY2024, which is 859.05% down from last year.
  • Per Myriad Genetics' latest filing, its Accumulated Depreciation & Amortization stood at $83.3 million for Q3 2025, which was down 2898.55% from $79.4 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Accumulated Depreciation & Amortization peaked at $119.9 million during Q4 2023, and registered a low of $79.4 million during Q2 2025.
  • Over the past 5 years, Myriad Genetics' median Accumulated Depreciation & Amortization value was $109.2 million (recorded in 2022), while the average stood at $106.1 million.
  • As far as peak fluctuations go, Myriad Genetics' Accumulated Depreciation & Amortization skyrocketed by 979.85% in 2023, and later crashed by 3101.65% in 2025.
  • Over the past 5 years, Myriad Genetics' Accumulated Depreciation & Amortization (Quarter) stood at $106.9 million in 2021, then grew by 2.15% to $109.2 million in 2022, then grew by 9.8% to $119.9 million in 2023, then fell by 8.59% to $109.6 million in 2024, then fell by 24.0% to $83.3 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $83.3 million for Q3 2025, versus $79.4 million for Q2 2025 and $83.5 million for Q1 2025.